Idil Yuksekel
Research Subjects
Research Interests
Idil Yuksekel has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Dias
ICBAS-Instituto de Ciências Biomédicas Abel Salazar (A.D., A.M., J.M., L.F.M.), University of Porto, Portugal
1 shared publication - Ana Aires
Neurology Department, Centro Hospitalar Universitário de São João, Porto, Portugal (R.D., A.A., P.C.).
1 shared publication - Ana Moutinho
ICBAS-Instituto de Ciências Biomédicas Abel Salazar (A.D., A.M., J.M., L.F.M.), University of Porto, Portugal
1 shared publication Beatriz Pinto
Neuroscience Department, Centro Hospitalar Universitário de Santo António, Porto, Portugal (R.V., J.F., B.P., V.A., L.I., J.L., J.S., J.P.F., M.J.M., D.G., R. Antunes, J.P.R., R.F., M.C., L.F.M.).
1 shared publication- Denis Gabriel
Neuroscience Department, Centro Hospitalar Universitário de Santo António, Porto, Portugal (R.V., J.F., B.P., V.A., L.I., J.L., J.S., J.P.F., M.J.M., D.G., R. Antunes, J.P.R., R.F., M.C., L.F.M.).
1 shared publication - Fernando Gonzalez-Ortiz
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
1 shared publication
Latest Publications
- 1 September 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (9) , 2353-2358
Plasma Brain-Derived Tau in Prognosis of Large Vessel Occlusion Ischemic Stroke
BACKGROUND: Large vessel occlusion acute ischemic stroke prognosis improved following the 2015 endovascular therapy (EVT) trials. Blood-based biomarkers may improve outcome prediction. We aimed to assess plasma brain-derived tau (BD-Tau) performance in predicting post-EVT large vessel occlusion acute ischemic stroke outcomes. METHODS: We included 2 temporally independent prospective cohorts of anterior circulation in patients with large vessel occlusion acute ischemic stroke who successfully recanalized post-EVT. We measured plasma BD-Tau, GFAP (glial-fibrillary-acidic-protein), NfL (neurofilament-light-chain), and total-Tau upon admission, immediately, 24 hours, and 72 hours post-EVT. Twenty-four-hour neuroimaging and 90-day functional outcomes were independently assessed using the Alberta Stroke Program Early Computed Tomography Score (good outcome: >7 or unchanged) and the modified Rankin Scale (favorable outcome P P P <0.001). CONCLUSIONS: Admission plasma BD-Tau accurately predicted 90-day functional outcomes in patients with large vessel occlusion acute ischemic stroke after successful EVT. The proposed model may predict functional outcomes using objective measures, minimizing human-related biases and serving as a simplified prognostic tool for AIS.
- 1 September 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (9) , 2353-2358
Plasma Brain-Derived Tau in Prognosis of Large Vessel Occlusion Ischemic Stroke
BACKGROUND: Large vessel occlusion acute ischemic stroke prognosis improved following the 2015 endovascular therapy (EVT) trials. Blood-based biomarkers may improve outcome prediction. We aimed to assess plasma brain-derived tau (BD-Tau) performance in predicting post-EVT large vessel occlusion acute ischemic stroke outcomes. METHODS: We included 2 temporally independent prospective cohorts of anterior circulation in patients with large vessel occlusion acute ischemic stroke who successfully recanalized post-EVT. We measured plasma BD-Tau, GFAP (glial-fibrillary-acidic-protein), NfL (neurofilament-light-chain), and total-Tau upon admission, immediately, 24 hours, and 72 hours post-EVT. Twenty-four-hour neuroimaging and 90-day functional outcomes were independently assessed using the Alberta Stroke Program Early Computed Tomography Score (good outcome: >7 or unchanged) and the modified Rankin Scale (favorable outcome P P P <0.001). CONCLUSIONS: Admission plasma BD-Tau accurately predicted 90-day functional outcomes in patients with large vessel occlusion acute ischemic stroke after successful EVT. The proposed model may predict functional outcomes using objective measures, minimizing human-related biases and serving as a simplified prognostic tool for AIS.